2015-05-15T13:17:18-05:00 2014-12-31 050409384 KAHN LITWIN RENZA & CO LTD 800 SOUTH STREET SUITE 300 WALTHAM MA 02453 990 2014-01-01 206745475 THE ADENOID CYSTIC CARCINOMA RESEARCH FOUNDATION ADEN 7812489699 PO BOX 442 NEEDHAM MA 02494 JEFFREY A KAUFMAN EXECUTIVE DIRECTOR 7812489699 2015-05-15 1 MEYER H LEVY P00036576 7815478800 2014 2016-03-07 17:11:31Z JEFFREY A KAUFMAN PO BOX 442 NEEDHAM MA 02494 1400618 0 X WWW.ACCRF.ORG X 2005 MA SUPPORTING RESEARCH INTO THE TREATMENT AND CURE OF ADENOID CYSTIC CARCINOMA 6 5 1 0 0 0 531408 1363695 0 0 5333 6303 228322 6306 765063 1376304 1414954 1045628 0 0 159224 159429 0 0 4783 321251 319980 1895429 1525037 -1130366 -148733 2149665 2054654 553087 606809 1596578 1447845 THE ADENOID CYSTIC CARCINOMA RESEARCH FOUNDATION (ACCRF) SUPPORTS RESEARCH INTO ADENOID CYSTIC CARCINOMA THAT WILL ACCELERATE THE DEVELOPMENT OF IMPROVED THERAPIES AND A CURE FOR THE DISEASE. 0 0 155509 130000 SPECIMENS AND MODELS: ACCRF SUPPORTS AND COORDINATES THE DEVELOPMENT AND DISTRIBUTION OF BIOBANKING, CELL LINE AND ANIMAL MODEL RESOURCES FOR RESEARCHERS. THESE RESOURCES ARE THE BUILDING BLOCKS UPON WHICH ALL BASIC, TRANSLATIONAL AND CLINICAL RESEARCH ARE CONSTRUCTED. 916805 865628 BASIC RESEARCH: ACCRF SUPPORTS AND COORDINATES THE DESCRIPTIVE AND FUNCTIONAL STUDIES THAT IDENTIFY THE MOLECULAR TARGETS AND PATHWAYS THAT PERMIT ADENOID CYSTIC CARCINOMA TO PROGRESS. BY FOCUSING ON THE MECHANISMS OF ACTION, RESEARCHERS MAY DISCOVER MORE QUICKLY THE ACHILLES' HEELS OF THE DISEASE. 387171 50000 TRANSLATION TO THE CLINIC: ACCRF SUPPORTS AND COORDINATES RESEARCH INTO TREATMENTS MOST LIKELY TO LEAD TO CLINICAL BENEFIT FOR ADENOID CYSTIC CARCINOMA PATIENTS. DRUG DISCOVERY, DRUG DEVELOPMENT, PRECLINICAL DRUG SCREENING AND CORRELATIVE STUDIES ARE CRUCIAL TO THE INITIATION AND OPTIMAL CONDUCT OF CLINICAL TRIALS. 1459485 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 1 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 0 0 0 0 0 1 1 0 0 0 0 X 6 5 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 0 1 1 0 0 MA NY CA CT FL MI NC NH NY OH PA VA X MARNIE A KAUFMAN 7814491757 60 SAVOY ROAD NEEDHAM MA 02492 JEFFREY A KAUFMAN EXECUTIVE DIRECTOR 50.00 X X 150000 0 0 RALPH MOLLIS TREASURER 5.00 X X 0 0 0 THOMAS DILENGE DIRECTOR 5.00 X 0 0 0 KARA GELB DIRECTOR 5.00 X 0 0 0 MARNIE A KAUFMAN DIRECTOR 25.00 X 0 0 0 DOUGLAS MEYER DIRECTOR 5.00 X 0 0 0 150000 0 0 1 0 0 0 0 71175 1292520 16815 1363695 6303 6303 30620 71175 24314 6306 6306 1376304 0 0 12609 743128 743128 302500 302500 150000 120000 25500 4500 9429 7543 1603 283 16750 16750 4212 4212 5179 5179 1370 1370 22347 22347 685 685 RESEARCH STUDIES EXPENS 263967 263967 STAFF DEVELOPMENT 2995 2995 LICENSES AND FEES 2475 2475 1525037 1459485 60769 4783 236409 122426 1913256 1932228 2149665 2054654 22978 23478 530109 583331 553087 606809 X 1596578 1447845 1596578 1447845 2149665 2054654 -148733 0 X 0 1 X 1 0 X 951993 2543071 1677911 531408 483168 6187551 951993 2543071 1677911 531408 483168 6187551 73115 6114436 3186 8741 9122 5333 6303 32685 6220236 78889 0.98300 0.99270 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 X 1400304 24000 24000 1376304 0 1376304 1549037 24000 24000 1525037 0 1525037 PART X, LINE 2: THE FOUNDATION IS EXEMPT FROM INCOME TAXES AS A PUBLIC CHARITY UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. MANAGEMENT BELIEVES THAT THE FOUNDATION OPERATES IN A MANNER CONSISTENT WITH THEIR TAX-EXEMPT STATUS AT BOTH THE STATE AND FEDERAL LEVEL. THE FOUNDATION ANNUALLY FILES IRS FORM 990 - RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX REPORTING VARIOUS INFORMATION THAT THE IRS USES TO MONITOR THE ACTIVITIES OF TAX-EXEMPT ENTITIES. THESE TAX RETURNS ARE SUBJECT TO REVIEW BY THE TAXING AUTHORITIES GENERALLY FOR A PERIOD OF THREE YEARS AFTER THEY WERE FILED. THE FOUNDATION'S TAX RETURNS FOR 2011, 2012 AND 2013 ARE SUBJECT TO EXAMINATION BY THE IRS. THE FOUNDATION CURRENTLY HAS NO TAX EXAMINATIONS IN PROGRESS. PART XI, LINE 4B - OTHER ADJUSTMENTS: PY GRANTS RETURNED FUNDRAISING EXPENSES INCLUDED IN FUNCTIONAL EXPENSES PART XII, LINE 2D - OTHER ADJUSTMENTS: PY GRANTS RETURNED PART XII, LINE 4B - OTHER ADJUSTMENTS: FUNDRAISING EXPENSES INCLUDED IN FUNCTIONAL EXPENSES 1 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION SUPPORT FOR RESEARCH RELATING TO ADENOID CYSTIC CARCINOMA 302500 0 0 0 0 0 0 302500 0 302500 EUROPE (INCLUDING ICELAND & GREENLAND) DEVELOPMENT OF C-MYC AS A TEST FOR ADENOID CYSTIC CARCINOMA 116100 CHECK OR FUND TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) DEVELOPMENT AND SCREENING OF ASSAYS FOR MYB INHIBITORS 174400 CHECK OR FUND TRANSFER EUROPE (INCLUDING ICELAND & GREENLAND) INTERNATIONAL CONSENSUS CONFERENCE ON SALIVARY GLAND CANCERS 10000 CHECK OR FUND TRANSFER 3 0 0 0 0 0 0 0 PART I, LINE 2: ALL FOREIGN GRANTS ARE MADE TO MAJOR RESEARCH INSTITUTIONS OR HOSPITALS WITH INTERNATIONAL REPUTATIONS. IN ADDITION TO INTERIM WRITTEN REPORTS ON RESEARCH PROJECTS AND A FINAL REPORT FOLLOWING PROJECT COMPLETION, ACCRF ANNUALLY MEETS WITH EACH OF THE FOREIGN GRANTEES TO RECEIVE AN ORAL REPORT ON THE RESEARCH PROJECTS. FRIENDS OF ACCRF EVENT 101795 71175 30620 5952 550 17812 101795 71175 30620 5952 550 17812 24314 6306 1 DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON MA 02215 042263040 501(C)(3) 44231 SUPPORT FOR STUDY OF IMMUNOLOGIC MODELS IN ADENOID CYSTIC CARCINOMA UNIVERSITY OF VIRGINIA - UVA HEALTH SYSTEM OFFICE OF SPONSORED PROGRAMS PO BOX 400195 CHARLOTTESVILLE VA 22904 546001796 501(C)(3) 352521 SUPPORT FOR STUDY OF MYB INHIBITORS AND COFACTORS IN ADENOID CYSTIC CARCINOMA MEMORIAL SLOAN-KETTERING CANCER CENTER 633 THIRD AVENUE 28TH FLOOR NEW YORK NY 10017 131924236 501(C)(3) 25000 SUPPORT FOR STUDY OF THE MYB-NFIB FUSION GENE IN ADENOID CYSTIC CARCINOMA PF THE BREAST TOCAGEN INC 3030 BUNKER HILL ST STE 230 SAN DIEGO CA 92109 261243872 501(C)(3) 101688 SUPPORT FOR STUDY OF RRV INFECTIVITY HARVARD MEDICAL SCHOOL 25 SHATTUCK ST BOSTON MA 02115 042103580 501(C)(3) 25000 SUPPORT FOR THE DISCOVERY OF MYB-SUPPRESSING COMPOUNDS UNIVERSITY OF FLORIDA PO BOX 100216 GAINESVILLE FL 32610 596002052 25000 SUPPORT FOR THE ESTABLISHMENT OF PERMANENT CELL CULTURES FROM HUMAN ADENOID CYSTIC CARCINOMA UNIVERSITY OF TEXAS SOUTHWESTERN 1801 INWOOD RD DALLAS TX 75235 756002868 25000 SUPPORT FOR THE STUDY OF ADENOID CYSTIC CARCINOMA CELL LINES UNIVERSITY OF MICHIGAN 500 S STATE STREET ANN ARBOR MI 48109 386006309 501(C)(3) 25000 SUPPORT FOR THE STUDY OF TARGETING ADENOID CYSTIC CARCINOMA INITIATING CELLS GEORGETOWN UNIVERSITY 3700 O ST NW WASHINGTON DC 20057 530196603 501(C)(3) 55000 SUPPORT FOR THE STUDY OF PATIENT TISSUE-DERIVED MODEL SYSTEMS FOR ADENOID CYSTIC CARCINOMA BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02115 900656139 501(C)(3) 39688 SUPPORT FOR THE DEVELOPMENT OF NOTCH-RELATED DIAGNOSTICS IN ADENOID CYSTIC CARCINOMA YALE UNIVERSITY PO BOX 1873 NEW HAVEN CT 06508 060646973 501(C)(3) 25000 SUPPORT FOR THE IVANOV CELL PROJECT 11 2 PART I, LINE 2: ACCRF TYPICALLY REQUIRES INTERIM REPORTING ON RESEARCH PROJECTS EVERY SIX MONTHS AS WELL AS A FINAL REPORT FOLLOWING PROJECT COMPLETION. FORM 990, PART VI, SECTION A, LINE 2 THE EXECUTIVE DIRECTOR, JEFFREY A. KAUFMAN, IS MARRIED TO A DIRECTOR ON THE BOARD, MARNIE A. KAUFMAN. FORM 990, PART VI, SECTION B, LINE 11 THE FORM 990 IS PREPARED BY THE EXTERNAL AUDITORS AND REVIEWED BY MANAGEMENT. ONCE ALL ARE SATISFIED WITH THE FORM, IT IS FINALIZED AND A COPY IS SENT TO ALL DIRECTORS. THE DIRECTORS ARE ASKED IF THEY HAVE ANY QUESTIONS OR COMMENTS AND A GENERAL REVIEW OF THE FORM IS CONDUCTED BY MANAGEMENT. REVISIONS AND CORRECTIONS ARE MADE AS NECESSARY. SUBSEQUENTLY, THE FORM IS SUBMITTED TO THE IRS. FORM 990, PART VI, SECTION B, LINE 12C A FORMAL PROCESS IS UNDERTAKEN EACH YEAR TO MONITOR AND ENFORCE THE CONFLICT OF INTEREST POLICY CONTAINED WITHIN THE BYLAWS. EACH JANUARY, AN ANNUAL SURVEY ON CONFLICTS OF INTEREST IS COMPLETED BY EVERY DIRECTOR AND OFFICER COVERING THE PRIOR CALENDAR YEAR. ALL BUSINESS RELATIONSHIPS, IF ANY, ARE REPORTED TO THE BOARD OF DIRECTORS. EXCLUDING ANY INTERESTED PARTIES, A MAJORITY OF REMAINING DIRECTORS DETERMINES WHETHER A CONFLICT OF INTEREST HAS OCCURRED AND WHETHER A MORE ADVANTAGEOUS TRANSACTION IS AVAILABLE TO THE FOUNDATION THAT WOULD NOT LEAD TO A CONFLICT OF INTEREST. THE BOARD IS CHARGED WITH TAKING APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION IN THE CASE OF A VIOLATION OF THE CONFLICT OF INTEREST POLICY. FORM 990, PART VI, SECTION B, LINE 15A A FORMAL STRATEGIC REVIEW, OBJECTIVE SETTING AND PERFORMANCE REVIEW PROCESS IS UNDERTAKEN EACH YEAR. THE BOARD OF DIRECTORS REVIEWS THE PERFORMANCE OF THE ORGANIZATION AND EXECUTIVE DIRECTOR, BASED ON GOALS AND OBJECTIVES PREVIOUSLY AGREED UPON DURING THE PRIOR CALENDAR YEAR AND ON A PERFORMANCE REPORT SUBMITTED BY THE EXECUTIVE DIRECTOR IN ADVANCE. THE INDEPENDENT DIRECTORS OF THE BOARD MEET SEPARATELY TO ASSESS THE EXECUTIVE DIRECTOR'S PERFORMANCE, AGREE ON A PROCESS TO INFORM THE EXECUTIVE DIRECTOR OF ANY AREAS OF NEEDED IMPROVEMENT, AND AGREE UPON A MERIT AND/OR COST OF LIVING SALARY INCREASE FOR THE DIRECTOR, SUBJECT TO AVAILABILITY OF FUNDS AND MAINTENANCE OF AN APPROPRIATE RATIO BETWEEN SUCH SALARY AND ACCRF FUNDRAISING/REVENUE TOTALS IN ANY GIVEN YEAR. THE BOARD OF DIRECTORS SETS PERFORMANCE OBJECTIVES AND METRICS FOR THE ORGANIZATION AND THE EXECUTIVE DIRECTOR FOR THE CURRENT CALENDAR YEAR. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS (ARTICLES OF INCORPORATION AND BY-LAWS), ITS CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS AVAILABLE UPON REQUEST. THE ORGANIZATION WILL MAIL COPIES UPON REQUEST OR PROVIDE COPIES TO THOSE WHO COME TO THE ADMINISTRATIVE OFFICES DURING NORMAL BUSINESS HOURS.